I just recently listened to a webinar where David (Dedi) Meiri discussed the marijuana research study in his laboratory at the Technion-Israel Institute of Technology. Meiri is best known for his work matching specific elements of cannabis to affect different kinds of cancer. When the interviewer asked the Israeli researcher which areas of medicine he thought marijuana used the most assure, the response was unexpected.
On top of what is currently known and dealt with … discomfort, sleep, epilepsy, stress and anxiety and these examples, I believe that a person of the important things that is still not being treated with marijuana … and I actually, really think in it, and in my laboratory I have sensational results, is dementia and Alzheimer’s.
There is a big and growing body of anecdotal accounts of the efficacy of cannabis for treating the symptoms of Alzheimer’s disease and dementia. The shortcomings and actual life-threatening risks connected with standard and often recommended pharmaceutical treatments for these conditions makes marijuana an especially engaging choice– specifically considering its strong security profile. But the requirement for research to corroborate these real-life findings is crucial, and Meiri’s Technion laboratory appears poised to deliver the goods.
In a follow up Zoom call, Dedi discussed his work on this subject:
Firstly, marijuana is extremely useful in improving lifestyle: minimizing stress and anxiety, improving sleep, minimizing violence. We know it from our deal with autistic kids, from treating PTSD, and other signs. We currently understand which strains are attaining this result and a lot of them are high CBD strains, with really low or no THC. Autistic kids in Israel are getting a stress extract with an extremely low amount of THC and it still minimizes violence, truly enhances sleep and lowers anxiety.
If we’re talking about improving quality of life of the Alzheimer’s client and their families … individuals with Alzheimer’s often struggle with bursts of anger and sleep conditions. So on that scale cannabis is very beneficial …
But Meiri likewise explains that for Alzheimer’s illness, like with cancer, marijuana might also have a role beyond palliative care. Just as his lab takes a look at the various chemovars and mixes of cannabinoids that can potentially detain cancer development, they are investigating the neuroprotective performance of these substances too.
With Alzheimer’s, on top of all the palliative treatment on the lifestyle, there is a question whether marijuana can also truly fight the dementia or improve the memory or the pathology of the illness itself. There are currently a couple of research studies that have actually shown that cannabis in low doses can be effective. It’s understood that the endocannabinoid system is involved in this process and in the development of Alzheimer’s. Decrease of Anandamide and 2AG and other endocannabinoids is in line with the progression of the illness.
Over the last three years, Meiri has actually been pursuing this line of research utilizing mouse and other Alzheimer’s disease models.
We evaluated a lot of cannabis chemovars and specified a couple of that are decreasing the amyloid plaques in the brain. We likewise identified the mechanisms that are triggered in the brain, how this happens, and why they are reducing the plaques. We have extremely strong outcomes revealing enhancement in the pathology of the disease in mice with rather advanced Alzheimer’s after treatment with particular molecules of cannabis. This consists of enhancements in the damage from the amyloid plaques in the brain and the neurons that were treated with the particular marijuana molecules, in addition to enhancement in their behavior as evidenced through numerous tests.
However, there is a big space in between the mice brain and the human brain, so I couldn’t inform you if it will operate in human patients …
To conquer that space, Meiri and his group are now in the process of getting approvals for a scientific trial to check the results of a full spectrum marijuana extract on clients.
It’s a medical trial on around 80 patients who suffer from serious Alzheimer’s disease, with violent habits, anxiety, anger and sleep conditions. We will treat them with cannabis to see if it can enhance their habits, make them calmer, more relaxed and assist them sleep much better. This is cannabis with an extremely low quantity of THC or without THC at all– an entire extract of a high CBD pressure. It’s not just sedation – you don’t give them THC and get them stoned and they’re just lying on the couch. It’s not that. It’s other substances and other results.
We also spoke about the crucial nuances between marijuana cultivars, and the necessity of looking beyond just THC and CBD.
We have cultivars that are improving a disease considerably, and we have cultivars that make the illness even worse, even though they have the same quantity of CBD and THC. It’s real for sleep disorders, several sclerosis, in Alzheimer’s and with a cancer.
If that’s the case, then what about all the cannabis medications that are merely made up of THC and CBD isolates in different ratios?
I think for certain indications, like pain, for example, it might be enough. The very same goes for multiple sclerosis, Alzheimer’s and even breast cancer … I have at least 6 various examples that I currently proved that it’s not the THC/CBD ratios, or it’s not enough.
So after ruling out simply CBD and THC, I asked him, what does he presume is making the difference?
I am 100%sure it’s not the THC and CBD since I currently eliminated them … however I’m still not really sure about the rest. I’m thinking that the flavonoids might be playing a big function there … Simply a couple of cannabinoids or families of cannabinoids, but primarily probably flavonoids and terpenoids – offer me a few more months and after that I’ll tell you.